

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

š

00000000000

In re Application of:

Alex Chenchik

Serial No.: 10/658.632

Filed:

9/8/03

For:

MAIL STOP DD

METHODS FOR GENE FUNCTION ANALYSIS

10101101171117121010

Confirmation No : 6082

Group Art Unit: 1645

Examiner: Unknown

CERTIFICATE OF MAILING 37 CFR 1.8

I hereby certify that this correspondence is being deposited on February 17, 2004 with the United States Postal Service as First Class Mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 28313-1450.

2/17/04

Esther Margues

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

The Applicants, and the Attorney who signs below on the basis of the information supplied by the inventor and the information in his file, submit herewith patents, publications, or other information of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. /

While the information submitted in this Information Disclosure Statement may be material pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is prior art for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97, this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other possibly material information as defined under 37 CFR § 1.56(a) exists.

The patents and/or publications submitted herewith are set forth on the attached Forms PTO-SB8A AND SB8B.

1

While we believe that no fee is due, if the sum of \$180.00 is due under 37 CFR § 1.17(p) pursuant to § 1.97, the Commissioner is hereby authorized to charge this fee, and any other fee necessary to make this submission timely, to the Deposit Account No.: 20-0782 (Order No. SBIO/0002/SB).

Respectfully submitted.

Sarah J. Brashears

Registration No. 37,087

MOSER, PATTERSON & SHERIDAN, L.L.P. 3040 Post Oak Blvd. Suite 1500

Houston, TX 77056

Telephone: (650) 330-2310

Facsimile: (650) 330-2314 Attorney for Applicant(s) & TRADERLA

PTO/SB/08a (08-03) RCE

Under the Paperwork Reduction Act of	U.S. Pat 1995, no persons are required to respond to a collec	ent and Trademark Office: U.S. DEPARTMENT tion of information unless it displays a valid OM	OF COMMERCE
ubstitute for form 1449A/PTO	Application Number	10/658,632	
	Filing Date	9/8/03	
NFORMATION DISCLOSURE	First Named Inventor	Alex Chenchik	
STATEMENT BY APPLICANT	Group Art Unit	1645	
الله الله	Examiner Name	Unknown	
(Use as many sheets as necessary)	Attorney Docket Number	SBIO/0002/SB	
Sheller 1 of 5	Submission Date	February 17, 2004	

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
iniuais	NO.	Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
/ADS/	A1	US-2001/0008771-A1	07/19/2001	Seibel et al.	\
/ADS/	A2	US-2002/0086356-A1	07/04/2002	Tuschle et al.	
/ADS/	A3	US-2002/0162126-A1	10/31/2002	Beach et al.	
/ADS/	A4	US-2003/0224055-A1	12/04/2003	Lewis et al.	
/ADS/	A5	US-2003/0224345-A1	12/04/2003	West et al.	
/ADS/	A6	US-2003/0224432-A1	12/04/2003	Myers et al.	X
/ADS/	A7	US-6,489,127-B1	12/03/2002	Exelixis, Inc.	
/ADS/	A8	US-6,506,559-B1	01/14/2003	Carnegie Institute of Washington	
/ADS/	A9	US-6,506,604-B2	01/14/2003	Cell Genesys, Inc.	
/ADS/	A10	US-6,518,035-B1	02/11/2003	Rosetta Inpharmatics, Inc.	
/ADS/	A11	US-6,573,099-B2	06/03/2003	Benitec Australia, Ltd.	
	ATZ				
	A13		-		
	A14				
					THE PERSON NAMED AND ADDRESS OF THE PERSON NAMED AND ADDRESS O

		F	OREIGN PATE	NT DOCUMENTS		
Examiner Cite		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	T ⁶
Initials*	Initials* No.1 Number-Kind Code ^{2 (f known)}	MM-DD-YYYY	Applicant of Cited Document			
/ADS/	B1	EP-1144623-B1	08/17/2000	Ribopharma AG	/	X Abstract Only
/ADS/	B2	WO-01/75164-A2	10/11/2001	Tuschi et al.		
/ADS/	В3	WO-02/055693-A2	07/18/2002	Kreutzer et al.	X	X Abstract Only
/ADS/	B4	WO-02/44321-A2	06/06/2002	Tuschl et al.		
/ADS/	B5	WO-03/006477-A1	01/23/2003	Zamore et al.		
/ADS/	B6	WO-03/022052-A1	03/20/2003	Baltimore et al.		

/Amber D. Steele/ 09/19/2008 **Date Considered**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include EXAMENT: filligit if emission, considered, whether or not claidon is in contemnate with MPEP 809. Draw fine through claiton of not in conformance and not considered, include with the contemnation of the content of the contemnation of the contemnation of the contemnation of the contemnation of the content of the con

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or relate to them to be read by the received by the 1.99 To be process) and policional Confederability by sowmed by 3.0 Life. 1.97 and 1.98. The 1.11 the collection is estimated to that the 2-barr to complete the particular partners; presented as submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you mouse to consider this form and/or suggestions for reducing this burstle, should be sent in the Differ ill dismost officer. U.S. Petrate and Trademark Officer, P. OB coll 146; yet 2.99. The considerability of the Confederability of the 1.99. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet 2

Translation is attached.

FEB

PTO/S8/08b (08-03) Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. ဖြန်းမှူးte for form 1449B/PTO Application Number 10/658.632 Filing Date 9/8/03 NEORMATION DISCLOSURE First Named Inventor Alex Chenchik STATEMENT BY APPLICANT Group Art Unit 1645 Examiner Name Unknown (Use as many sheets as necessary) Attorney Docket Number SBIO/0002/SB of 5 Submission Date February 17, 2004

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ADS/	1	Michiels, Frits et al. "Arrayed adenoviral expression libraries for functional screening." Nature Biotechnology. November 2002 20: 1154-1157.	
/ADS/	2	"BD Retro-X™ Q Vectors New self-inactivating vectors engineered to produce higher titers." <u>Clontechniques.</u> July 2002 2 pages	
/ADS/	3	Reddy, Ram et al. *The Capped U6 Small Nuclear RNA is Transcribed by RNA Polymerase III.* *The Journal of Biological Chemistry. January 1987 262(1): 75-81.	
/ADS/	4	Singh, Ravinder et al. "Capping of Mammalian U6 Small Nuclear RNA in Vitro is Directed by a Conserved Stem-Loop and AUAUAC Sequence: Conversion of a Noncapped RNA into a Capped RNA: Mollccular and Cellular Biology. Mar	
	6	densen, Allen. "A combinatorial cell based approach, CellSoroen." I for target identification." citation requires additional information	
/ADS/	6	Ohkawa, Jun et al. "Control of the Functional Activity of an Antisense RNA by a Tetracycline- Responsive Derivative of the Human U6 snRNA Promoter."	
/ADS/	7	Chen, Yill et al. "Development of RNA interference revertants in Trypanosoma brucei cell lines generated with a double stranded RNA expression construct driven by two opposing promoters." Molecular & Biochemical Parasistology. 2002 4078: 1-4 of 5.	
/ADS/	8	Shi, Leming. "DNA Microarray (Genome Chip)" <u>DNA Microarray (Genome Chip) - Monitoring the Genome on a Chip</u> . 8 July 2003 https://www.gene-chips.com/ (pages 2, 11, 12, 13 and 15 of 19).	
/ADS/	9	Tuschi, Thomas. "Expanding small RNA interference." Nature Biotechnology. May 2002 20: 446-448.	
/ADS/	10	Piano, Fabio et al. "Gene Clustering Based on RNAi Phenotypes of Ovary-Enriched Genes in C. elegans." Current Biology. November 2002 12: 1959-1964.	
/ADS/	11	Brazma, Alvis et al. "Gene expression data analysis." <u>FEBS Letters</u> . 2000 480: 17-24.	
/ADS/	12	Tiscomia, Gustavo et al. 'A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA.' PNAS Early Edition. 1-5 cwww.pnas.org/cgi/doi/10.073/pnas.0437912100>. epub 1/27/2003	

/Amber D. Steele/ Examiner Date Considered 09/19/2008 *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 39 U.S. (1.2 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from the full CPPTO. Time will vary depending upon the included scase, here comments on the amount of time you remount of time you remount of time you remove the complete this foliam and/or suggestions for reducing this butters, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, V.A. 22313-1450. If you need SSIO PEES OR COMPLETED PROMIS TO THIS ADDRESS. SEMD TO: Commissioner for Patents, P.O. Box 1459, Alexandria, V.A. 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

e for form 1449B/PTO

Sheet 3

(Use as many sheets as necessary)

of 5

Application Number	10/658,632	
Filing Date	9/8/03	
First Named Inventor	Alex Chenchik	
Group Art Unit	1645	
Examiner Name	Unknown	
Attorney Docket Number	SBIO/OOO2/SB	
Submission Date	February 17, 2004	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	13	Runinsun, igur B. et al. "Genetic Suppressor Elements in the Characterization and — date? Identification of Tumor Suppressor Genes." Methods in Molecular Diology. 222. 411-434.	
/ADS/	14	Reed, Ken C. "High throughput target identification and validation <i>in vitro</i> and <i>in vivo</i> ." <u>RNAi 2003 Boston Meeting Proceedings</u> . May 2003 1 page, abstract only	
/ADS/	15	Kawasaki, Hiroaki et al. "Identification of genes that function in the TNF- σ -mediated apoptotic pathway using randomized hybrid ribozyme libraries." Nature Biotechnology. April 2002 20: 376-380.	
/ADS/	16	Wang, Zefeng et al. "Inhibition of <i>Trypanosoma brucei</i> Gene Expression by RNA Interference User an Integratable Vector with Opposing 17 Promoters." <u>The Journal of Biological</u> Chemistry. December 2000 275(51): 40174-40179.	
/ADS/	17	Qin, Xiao-Feng et al. * Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCRS.* PNAS. January 2003 100(1): 183-188.	
/ADS/	18	Walhout, Albertha J.M. et al. * Integrating Interactome, Phenome, and Transcriptome Mapping Data for the <i>C. elegans</i> Germline.* <u>Current Biology</u> . November 2002 12: 1952-1958.	
/ADS/	19	Famulok, Michael et al. "In vivo-applied functional RNAs as tools in proteomics and genomics research." <u>Trends in Biotechnology</u> . November 2002 20(11): 462-466.	
/ADS/	20	Voorhoeve, P. Mathijs et al. "Knockdown stands up." <u>Trends in Biotechnology</u> . January 2003 21(1): 2-4.	
/ADS/	21	Stewart, Sheila A. et al. "Lentivirus-delivered stable gene silencing by RNAi in primary cells." RNA. 2003 9:493-501.	
/ADS/	22	Shi, Yang. "Mammalian RNAi for the masses." <u>Trends in Genetics</u> . January 2003 19(1): 9-12.	
/ADS/	23	Shumyatsky, Gleb et al. "Methylphosphate cap structure increases the stability of 7SK, B2 AND U6 small RNAs in <i>Xenopus oocytes</i> ." <u>Nucleic Acids Research</u> . 1993 21(20): 4756-4761.	
/ADS/	24	"Microarrays: Chipping Away at the Mysteries of Science and Medicine." National Center for Biotechnology Information. 1-12. http://www.nob.infin.nih.gov/Abou/bprimer/microarrays.html>. revised 2/10/2003	

Examiner /Amber D. Steele/ Date Considered 09/19/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to epplicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by \$3 U.S.C. 122 and 37 CFR 1.1 This excellent is estimated to take 2 hours to compate, including gathering, preparing, and ucheming the completed application from to the USPTO. Time will vary depending upon the confidence of the completed application from to the USPTO. Time will vary depending upon the confidence of the completed application from to the USPTO. Time will vary depending upon the confidence of the USP peters and a Transmiss Office, P.O. Dox 1450, Active 32 2313-1450, USP NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrila, VA 22313-1450. If you need assistance in completing the form, and 11-600-PTO-9199 (1-600-766-9199) and select option.

Sheet 4

of 5

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMER
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 14498/PTO Application Number 10/658,632

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

croding and respond to respond to a control	addit of afficiations of this as it displays a valid GMD construct the	UIIIU
Application Number	10/658,632	7
Filing Date	9/8/03	
First Named Inventor	Alex Chenchik	
Group Art Unit	1645	1
Examiner Name	Unknown	
Attorney Docket Number	SBIO/OOO2/SB	T
Submission Date	February 17, 2004	ナ

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ADS/	25	Singh, Ravinder et al. " γ -Monomethyl phosphate: A cap structure in spliceosomal U6 small nuclear RNA." <u>Proc. Natl. Acad. Sci</u> . November 1989 86: 8280-8283.	
/ADS/	26	*pPUR.* BD Biosciences. 10 June 2003 <http: lechinfo="" ppur.shtml="" vectors="" vectorsm-q="" www.clontech.com="">. 3 pages</http:>	
/ADS/	27	Barton, Gregory M. et al. "Retroviral delivery of small interfering RNA into primary cells." PNAS. November 2002 99(23): 14943-14945.	
/ADS/	28	Ilives, Heini et al. "Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study." <u>Gene</u> . 1996 171: 203-208.	
/ADS/	29	Devroe, Eric et al. "Retrovirus-delivered siRNA." <u>BioMed Central</u> . August 2002 2: 15. http://www.biomedcentral.com/1472-6750/2/15 >. 5 pages	
/ADS/	30	Hannon, Gregory J. "RNA interference." Nature. July 2002 418: 244-251.	
/ADS/	31	Willis, Ian M. *RNA polymerase III: Genes, factors and transcriptional specificity.* <u>Eur. J. Biochem</u> . 1993 212: 1-11.	
/ADS/	32	Burke, Adrienne J. "Short Interfering Sensation." Genome Technology. May 2003: 36-44.	
/ADS/	33	Kunkel, Gary R. et al. 'Transcription of a human U6 small nuclear RNA gene <i>in vivo</i> withstands deletion of intragenic sequences but not of an upstream TATATA box.' Nucleic Acids Research, 1989 17(18): 7371-7379.	_
/ADS/	34	Pfelfer, Alexander et al. "Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos." <u>PNAS</u> . February 2002 99(4): 2140-2145.	
/ADS/	35	Miyagishi, Makoto et al. "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells." <u>Nature Biotechnology.</u> May 2002 19: 497-500.	
/ADS/	36	Kunkel, Gary R. et al. "U6 small nuclear RNA is transcribed by RNA polymerase III." Proc. Natl. Acad. Sci. November 1986 83:8575-8579.	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. I Applicant's unique citation designation number (optional), 2 Applicant is to piece a check mark here if English language

Date Considered

09/19/2008

/Amber D. Steele/

Examiner

This collection of information is required by 37 CPR 1.98. The information is required to obtain or retain a boreful by the public which is to file (and by the USPTO to process) as application. Confidentially is governed by 32 USC. 12 22 and 37 CPR 1.14 This collection is estimated to take 2 hours to compale, including patheting, preparing, and unbraining the completed application from to the USPTO. Time will very depending upon the individual sense. The confidential collection from to the USPTO. Time will very depending upon the individual sense. The confidential collection from the USPTO. Time will very depending upon the individual sense. The Care of the Confidential Collection from the USPTO. The Confidential Collection for the USPTO. The Confidential Collection for the USPTO. The Confidential Collection for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450. If you need assistance in completing the form, call 1-600-PTO-1980 (1-600-P68-979) and select option.

of 5

+

Sheet 5

Approved for use through 06/30/2006, OMB 0651-0031
Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

February 17, 2004

Under the Paperwork Reduction Act of 1995,		ent and Trademark Office: U.S. DEPARTMENT OF COMMER(tion of information unless it displays a valid OMB control numb
Substitute for form 1449B/PTO	Application Number	10/658,632
	Filing Date	9/8/03
INFORMATION DISCLOSURE	First Named Inventor	Alex Chenchik
STATEMENT BY APPLICANT	Group Art Unit	1645
	Examiner Name	Unknown
(Use as many sheets as necessary)	Attorney Docket Number	SBIO/OOO2/SB

Submission Date

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ADS/	37	"Viral Expression Systems Overview: Many delivery choices for targeting virtually every cell type." <u>CLONTECHniques</u> . April 2001 www.clontech.com 2 pages	
	/		
		X	
	/		/
Examiner		/Amber D. Steele/ Date Considered 09/19/200	8

"EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 649. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language transition is statement.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 3 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to compete, including pathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending up the completed application from to the USPTO. Time will vary depending up to the completed application from the USPTO. Time will vary depending up to fire of the completed application from the USPTO. The will vary depending up to the complete of the USPTO. The view of the VIEW of the USPTO. The VIEW of the USPTO. The VIEW of the USPTO. The VIEW of the